Capstone Therapeutics announced consolidated earnings results for the year ended December 31, 2013. For the year, the company reported net loss attributable to stock holders of $3,921,000 or $0.10 basic and diluted per share compared to net loss attributable to stock holders of $3,580,000 or $0.09 basic and diluted per share of prior year. Loss from continuing operations was $4,114,000 against $4,053,000 of prior year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.625 USD | -7.50% | -7.50% | -11.06% |
04-01 | Capstone Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Capstone Holding Corp. Announces Change in Board of Directors | CI |
1st Jan change | Capi. | |
---|---|---|
-11.06% | 729K | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- CAPS Stock
- News Capstone Holding Corp.
- Capstone Therapeutics Announces Consolidated Earnings Results for the Year Ended December 31, 2013